8-K filing — Moleculin Biotech, Inc. (MBRX)
Filed: 2026-08-31 AccNo: 0001437749-26-029336 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial Evaluating Annamycin In R/R AML During Investor Segment
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share
Moleculin Biotech Stock Is Sinking Friday: What's Going On?
Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.